Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-09-08 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - 4DX 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from 4DMEDICAL LIMITED regarding the quotation of securities issued due to options being exercised or convertible securities being converted. It details the number and type of securities to be quoted, issue dates, prices, and the resulting issued capital. This type of document is a formal application to the ASX for the quotation of new securities and is a regulatory announcement related to capital changes. It is not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues and related capital structure changes.
2025-09-08 English
Notification regarding unquoted securities - 4DX 6 pages 18.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options and securities by 4DMEDICAL LIMITED. It includes specifics such as security codes, issue dates, number of securities issued, and compliance with ASX Listing Rules. The content focuses on the notification of new securities issued, not on financial results, management changes, or other report types. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or capital changes. The document length is 6550 characters, sufficient to contain detailed issuance information rather than a brief announcement. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2025-09-08 English
Notification regarding unquoted securities - 4DX 7 pages 23.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted securities under an employee incentive scheme, including dates, security codes, quantities, and whether securities were issued to key management personnel. It is a formal notification to the ASX about securities issuance, not a financial report or earnings release. The content matches the description of announcements regarding new share issues or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is 8222 characters, which is substantive and contains detailed issuance data, confirming it is not merely an announcement of a report or a certification.
2025-09-08 English
Application for quotation of securities - 4DX 8 pages 24.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement related to the quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and conversion of options into ordinary shares, the number of securities to be quoted, issue dates, and other related information. This type of document is a formal application for listing new or converted securities on the exchange, which corresponds to announcements about share issues or capital changes. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing or proxy statement. The document is lengthy (over 10,000 characters) and contains detailed information about the securities issued and their classification. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2025-09-08 English
Cleansing Notice 1 page 215.2KB
Regulatory Filings Classification · 100% confidence The document is a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) related to the issue of shares by 4DMedical Limited. It details the issuance of shares on exercise of options and compliance with relevant disclosure provisions. The document is short (2074 characters) and is a formal regulatory notice about share issuance without disclosure, not a financial report or detailed filing. It does not contain financial statements or management discussion, nor is it an announcement of a meeting or voting results. This fits the definition of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-09-08 English
4DX signs agreements with national lung screening sites 3 pages 346.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 8 September 2025 from 4DMedical Limited. It details new agreements and collaborations with a global pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging to deploy lung health screening and imaging software. The content focuses on business partnerships, product deployment, and program rollouts rather than financial results, regulatory filings, or management changes. There are no financial statements, earnings data, or regulatory certifications included. The document is a corporate announcement about collaborations and contracts, typical of a Capital/Financing Update or business development announcement. Given the nature of the content—announcing agreements and business collaborations related to product deployment and program support—it fits best under Capital/Financing Update (CAP). The document length (8906 characters) and detailed content support this classification with high confidence.
2025-09-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.